Skip to main navigation
Theratechnologies Inc. Theratechnologies Inc.

    About

  • About
    • About Us
    • Board of Directors
    • Leadership Team
    • Scientific Consultants & Advisors
    • Awards
  • Medicines & Pipeline

  • Medicines & Pipeline
    • Medicines
      • Trogarzo®
      • EGRIFTA SV®
    • Pipeline & Science
      • HIV
        • F8 in HIV-Associated Excess Abdominal Fat
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Hepatology
        • Tesamorelin for the Potential Treatment of NASH
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Oncology
        • SORT1+ Technology™
        • TH1902
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Expanded Access Policy
      • Grants/ISRs/IITs
  • IR Nav

  • Investors
    • Overview
    • News, Events & Presentations
      • Press Releases
      • Company Announcements
      • Events
      • Corporate Presentations
    • Stock Information
      • Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • SEDAR Filings
      • Financial Reports
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Investor Resources
      • Contact IR
      • FAQs
  • Corporate Responsibility

  • Corporate Responsibility
  • Careers

  • Careers
  • Contact Us

  • Contact Us
  • en
    • en
    • fr
  • btn Alerts

  • Sign up for Email Alerts

Social icons

Bio Details

Dale Weil, MBA

Corporate Director

Dale Weil, MBA

Mrs. Dale Weil was elected to the Board of Directors of Theratechnologies in 2017.

She is currently Executive Director of the Teresa Dellar Palliative Care Residence and Montreal Institute for Palliative Care. She is also a Director for Tetra Bio-Pharma, McGill University Health Centre, and the “Alliance des maisons de soins palliatifs du Québec”.

Previously, Mrs. Weil was with McKesson Canada Corporation. From 1999 to 2018, she held leadership roles including Vice President and General Manager Pharmaceutical Solutions, Senior Vice President Integrated Healthcare and Pharmaceutical Solutions, Senior Vice President Integrated Healthcare Solutions, Strategy and Business Development, Senior Vice President Retail Banner Management Services, and Senior Advisor to the President.

Prior to joining McKesson Canada, Mrs. Weil spent 20 years at John Labatt Ltd, Ault Foods and Parmalat Canada in progressive roles in marketing, research, strategy, sales, and general management.

Ms. Weil holds a BSC in Marine Biology, MBA from McGill University and is a certified director from the ICD Directors Education Program.

  • Member of the Nominating and Corporate Governance Committee

Headquarters

Theratechnologies inc.
2015 Peel Street, 11th Floor
Montréal, Québec
Canada H3A 1T8
Phone: 514 336-7800
Fax: 514 331-9691

European Headquarters

Theratechnologies Europe Limited
2 Hume Street, 4th floor
Dublin 2
Ireland D02 DV24
Phone: +353 1 215 0650
europe@theratech.com

Investor Relations

Elif McDonald
Senior Director, Investor Relations
Phone: +1-438-315-8563
ir@theratech.com

US Headquarters

Theratechnologies U.S., Inc.
101 Hudson Street
21st Floor
Jersey City, New Jersey 07302

Main Nav

  • Home
  • About
  • Medicines & Pipeline
  • Investors
  • Corporate Responsibility
  • Careers
  • Contact Us
©2023 - Theratechnologies Inc.

Legal Nav

  • Terms of Use
  • Privacy

Search

Theratechnologies